Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
26.08. | Gilead poised to bring twice-yearly HIV PrEP to EU | ||
26.08. | Roche breaks ground on US manufacturing facility | ||
26.08. | Alzheimer's drug Leqembi launched in first EU markets | ||
25.08. | Rumour partly confirmed as AbbVie acquires Gilgamesh drug | ||
25.08. | Radiopharma CDMO Nucleus names former FDA boss as CEO | ||
25.08. | RWE study shows promise for digital treatment of adult ADHD | ||
25.08. | Argenx poised to expand Vyvgart market off new phase 3 data | ||
22.08. | Ro taps Serena Williams as celebrity GLP-1 ambassador | ||
22.08. | As Streeting threatens no deal, talks on drug levy collapse | ||
22.08. | Streeting threatens 'no deal' with industry on drug levy | ||
22.08. | Twin Health raises $53m, as study backs 'digital twin' AI | ||
22.08. | Dynavax has GSK's shingles vaccine in its sights | ||
22.08. | Ionis brings long-acting treatment option to HAE patients | ||
21.08. | Gilead buys in vivo cell therapy firm Interius for $350m | ||
21.08. | EU-US trade deal includes 15% pharma tariff | ||
21.08. | J&J earmarks $2bn for facility in North Carolina | ||
21.08. | After shooting, HHS staff ask RFK Jr to tone down rhetoric | ||
21.08. | Nicox plans filings for glaucoma after phase 3 win | ||
21.08. | NICE backs bladder cancer duo that can double survival | ||
20.08. | Iterum brings first oral penem antibiotic to US market | ||
20.08. | Swedish digital therapy firm Mindler buys UK rival | ||
20.08. | PTC Therapeutics stung by FDA decision not to approve rare disease drug | ||
20.08. | New NHS diabetes strategy could raise GLP-1 drug use | ||
20.08. | CSL will slash headcount and hive off vaccine business | ||
20.08. | Viking felled by dropout rates in oral obesity drug trial |